{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T21:52:51Z","timestamp":1772574771246,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"National High Technology Research and Development Program of China","award":["2012AA02A501"],"award-info":[{"award-number":["2012AA02A501"]}]},{"name":"Molecular Classification, Personalized Diagnosis and Therapy of Nasopharyngeal Carcinoma","award":["2006AA02A404"],"award-info":[{"award-number":["2006AA02A404"]}]},{"name":"Sun Yat-Sen University Clinical Medical Research Project 5010","award":["20130008"],"award-info":[{"award-number":["20130008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2517-5","type":"journal-article","created":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T11:21:45Z","timestamp":1468408905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Phase I\/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab\u00ae-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma"],"prefix":"10.1186","volume":"16","author":[{"given":"Yan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunpeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,13]]},"reference":[{"key":"2517_CR1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5732\/cjc.010.10377","volume":"30","author":"SM Cao","year":"2011","unstructured":"Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011;30:114\u20139.","journal-title":"Chin J Cancer"},{"key":"2517_CR2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2147\/TCRM.S47434","volume":"10","author":"SH Hutajulu","year":"2014","unstructured":"Hutajulu SH, Kurnianda J, Tan IB, Middeldorp JM. Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma. Ther Clin Risk Manag. 2014;10:721\u201336.","journal-title":"Ther Clin Risk Manag"},{"key":"2517_CR3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.anorl.2010.10.003","volume":"128","author":"Y Bensouda","year":"2011","unstructured":"Bensouda Y, Kaikani W, Ahbeddou N, Rahhali R, Jabri M, Mrabti H, et al. Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis. 2011;128:79\u201385.","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"2517_CR4","unstructured":"National Cancer Institute [Internet]. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Head and Neck Cancers Version 2.2014 [cited 2014 Oct 9]. Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp"},{"issue":"7","key":"2517_CR5","doi-asserted-by":"crossref","first-page":"vii83","DOI":"10.1093\/annonc\/mds266","volume":"23","author":"AT Chan","year":"2012","unstructured":"Chan AT, Gr\u00e9goire V, Lefebvre JL, Licitra L, Hui EP, Leung SF, et al. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(7):vii83\u20135.","journal-title":"Ann Oncol"},{"key":"2517_CR6","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s12094-013-1094-1","volume":"15","author":"R Mes\u00eda","year":"2013","unstructured":"Mes\u00eda R, Pastor M, Grau JJ, Del Barco E, SEOM. SEOM clinical guidelines for the treatment of nasopharyngeal carcinoma 2013. Clin Transl Oncol. 2013;15:1025\u20139.","journal-title":"Clin Transl Oncol"},{"key":"2517_CR7","first-page":"161","volume":"9","author":"TE Ciuleanu","year":"2004","unstructured":"Ciuleanu TE, Fountzilas G, Ciuleanu E, Plataniotis M, Todor N, Ghilezan N. Paclitaxel and carboplatin in relapsed or metastatic nasopharyngeal carcinoma: a multicenter phase II study. J BUON. 2004;9:161\u20135.","journal-title":"J BUON"},{"key":"2517_CR8","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0959-8049(98)00280-9","volume":"34","author":"W Yeo","year":"1998","unstructured":"Yeo W, Leung TW, Chan AT, Chiu SK, Yu P, Mok TS, et al. A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer. 1998;34:2027\u201331.","journal-title":"Eur J Cancer"},{"key":"2517_CR9","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00432-012-1219-x","volume":"138","author":"Y Jin","year":"2012","unstructured":"Jin Y, Cai XY, Shi YX, Xia XY, Cai YC, Cao Y, et al. Comparison of 5 cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2012;138:1717\u201325.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2517_CR10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00280-012-2020-x","volume":"71","author":"C Chen","year":"2013","unstructured":"Chen C, Wang FH, An X, Luo HY, Wang ZQ, Liang Y, et al. Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and\/or recurrent nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 2013;71:371\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2517_CR11","first-page":"348","volume":"18","author":"E Mostafa","year":"2006","unstructured":"Mostafa E, Nasar MN, Rabie NA, Ibrahim SA, Barakat HM, Rabie AN. Induction chemotherapy with paclitaxel and cisplatin, followed by concomitant cisplatin and radiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. J Egypt Natl Canc Inst. 2006;18:348\u201356.","journal-title":"J Egypt Natl Canc Inst"},{"key":"2517_CR12","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/cncr.23687","volume":"113","author":"SS Leong","year":"2008","unstructured":"Leong SS, Wee J, Rajan S, Toh CK, Lim WT, Hee SW, et al. Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer. 2008;113:1332\u20137.","journal-title":"Cancer"},{"key":"2517_CR13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cncr.20804","volume":"103","author":"SS Leong","year":"2005","unstructured":"Leong SS, Wee J, Tay MH, Toh CK, Tan SB, Thng CH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination. Cancer. 2005;103:569\u201375.","journal-title":"Cancer"},{"key":"2517_CR14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1023\/A:1008390929826","volume":"10","author":"EH Tan","year":"1999","unstructured":"Tan EH, Khoo KS, Wee J, Fong KW, Lee KS, Lee KM, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol. 1999;10:235\u20137.","journal-title":"Ann Oncol"},{"key":"2517_CR15","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","volume":"37","author":"H Gelderblom","year":"2001","unstructured":"Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590\u20138.","journal-title":"Eur J Cancer"},{"key":"2517_CR16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.critrevonc.2014.06.001","volume":"92","author":"A Vi\u00fadez","year":"2014","unstructured":"Vi\u00fadez A, Ram\u00edrez N, Hern\u00e1ndez-Garc\u00eda I, Carvalho FL, Vera R, Hidalgo M. Nab-paclitaxel: A flattering facelift. Crit Rev Oncol Hematol. 2014;92:166\u201380.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2517_CR17","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O\u2019Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794\u2013803.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2517_CR18","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/jco.2007.25.18_suppl.1038","volume":"25","author":"Z Guan","year":"2007","unstructured":"Guan Z, Feng F, Li QL, Jiang Z, Shen Z, Yu S, et al. Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC) [abstract]. J Clin Oncol. 2007;25(1):1038.","journal-title":"J Clin Oncol"},{"key":"2517_CR19","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","volume":"30","author":"MA Socinski","year":"2012","unstructured":"Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30:2055\u201362.","journal-title":"J Clin Oncol"},{"issue":"15","key":"2517_CR20","doi-asserted-by":"crossref","first-page":"TPS7618","DOI":"10.1200\/jco.2012.30.15_suppl.tps7618","volume":"30","author":"V Hirsh","year":"2012","unstructured":"Hirsh V, Okamoto I, Hon JK, Dakhil SR, Page RD, Orsini J, et al. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Analysis of patient-reported neuropathy and taxane-associated symptoms. J Clin Oncol. 2012;30(15):TPS7618.","journal-title":"J Clin Oncol"},{"key":"2517_CR21","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jnci\/djk196","volume":"99","author":"A Ardizzoni","year":"2007","unstructured":"Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847\u201357.","journal-title":"J Natl Cancer Inst"},{"key":"2517_CR22","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mdr156","volume":"23","author":"MD Galsky","year":"2012","unstructured":"Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012;23:406\u201310.","journal-title":"Ann Oncol"},{"key":"2517_CR23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1479-5876-10-27","volume":"10","author":"H-Y Wang","year":"2012","unstructured":"Wang H-Y, Li Y-Y, Shao Q, Hou JH, Wang F, Cai MB, et al. Secreted protein acidic and rich in cysteine (SPARC) is associated with nasopharyngeal carcinoma metastasis and poor prognosis. J Transl Med. 2012;10:27.","journal-title":"J Transl Med"},{"key":"2517_CR24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"key":"2517_CR25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2008","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008;45:228\u201347.","journal-title":"Eur J Cancer"},{"issue":"2","key":"2517_CR26","first-page":"237","volume":"55","author":"FA Sinicrope","year":"1995","unstructured":"Sinicrope FA, Ruan SB, Cleary KR, et al. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995;55(2):237\u201341.","journal-title":"Cancer Res"},{"key":"2517_CR27","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0046-8177(87)80412-4","volume":"18","author":"FB Fromowitz","year":"1987","unstructured":"Fromowitz FB, Viola MV, Chao S, Oravez S, Mishriki Y, Finkel G, et al. Ras p21 expression in the progression of breast cancer. Hum Pathol. 1987;18:1268\u201375.","journal-title":"Hum Pathol"},{"key":"2517_CR28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.oraloncology.2003.10.010","volume":"40","author":"V Adamo","year":"2004","unstructured":"Adamo V, Ferraro G, Pergolizzi S, Sergi C, Laudani A, Settineri N, et al. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol. 2004;40:525\u201331.","journal-title":"Oral Oncol"},{"key":"2517_CR29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1179\/joc.2002.14.2.207","volume":"14","author":"M Basaran","year":"2002","unstructured":"Basaran M, Bavbek SE, G\u00fcll\u00fc I, Demirelli F, Sakar B, Tenekeci N, et al. A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer. J Chemother. 2002;14:207\u201313.","journal-title":"J Chemother"},{"key":"2517_CR30","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2001.19.4.1088","volume":"19","author":"AA Forastiere","year":"2001","unstructured":"Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, et al. Phase III comparison of high-dose paclitaxel\u2009+\u2009cisplatin\u2009+\u2009granulocyte colony-stimulating factor versus low-dose paclitaxel\u2009+\u2009cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol. 2001;19:1088\u201395.","journal-title":"J Clin Oncol"},{"key":"2517_CR31","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2005.01.057","volume":"23","author":"MK Gibson","year":"2005","unstructured":"Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:3562\u20137.","journal-title":"J Clin Oncol"},{"key":"2517_CR32","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1023\/A:1008260817878","volume":"8","author":"L Licitra","year":"1997","unstructured":"Licitra L, Capri G, Fulfaro F, Hussain MH, DeConti RC, Ensley J, et al. Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial. Ann Oncol. 1997;8:1157\u20138.","journal-title":"Ann Oncol"},{"key":"2517_CR33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1023\/A:1008298915121","volume":"9","author":"F Th\u00f6dtmann","year":"1998","unstructured":"Th\u00f6dtmann F, Theiss F, Kemmerich M, Heinrich B, Laubenbacher C, Quasthoff S, et al. Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 1998;9:335\u20137.","journal-title":"Ann Oncol"},{"issue":"4","key":"2517_CR34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2217\/fon.12.25","volume":"8","author":"RA Soo","year":"2012","unstructured":"Soo RA, Kawaguchi T, Loh M, Ou SH, Shieh MP, Cho BC, et al. Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. Future Oncol. 2012;8(4):451\u201362.","journal-title":"Future Oncol"},{"key":"2517_CR35","first-page":"623139","volume":"2012","author":"MS Surapaneni","year":"2010","unstructured":"Surapaneni MS, Das SK, Das NG. Designing Paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. ISRN Pharmacol. 2010;2012:623139.","journal-title":"ISRN Pharmacol"},{"key":"2517_CR36","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/jnci\/94.21.1614","volume":"94","author":"AT Chan","year":"2002","unstructured":"Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002;94:1614\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"2517_CR37","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","volume":"350","author":"JC Lin","year":"2004","unstructured":"Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J. 2004;350:2461\u201370.","journal-title":"N Engl J"},{"key":"2517_CR38","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1002\/cncr.25932","volume":"117","author":"X An","year":"2011","unstructured":"An X, Wang FH, Ding PR, Deng L, Jiang WQ, Zhang L, et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic\/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer. 2011;117:3750\u20137.","journal-title":"Cancer"},{"key":"2517_CR39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1749-6632.2001.tb03866.x","volume":"945","author":"RK Ngan","year":"2001","unstructured":"Ngan RK, Lau WH, Yip TT, Cho WC, Cheng WW, Lim CK, et al. Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy. Ann N Y Acad Sci. 2001;945:73\u20139.","journal-title":"Ann N Y Acad Sci"},{"key":"2517_CR40","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.oraloncology.2013.02.006","volume":"49","author":"CL Hsu","year":"2013","unstructured":"Hsu CL, Chan SC, Chang KP, Lin TL, Lin CY, Hsieh CH, et al. Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma. Oral Oncol. 2013;49:620\u20135.","journal-title":"Oral Oncol"},{"key":"2517_CR41","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.oraloncology.2013.12.011","volume":"50","author":"TT Yip","year":"2014","unstructured":"Yip TT, Ngan RK, Fong AH, Law SC. Application of circulating plasma\/serum EBV DNA in the clinical management of nasopharyngeal carcinoma. Oral Oncol. 2014;50:527\u201338.","journal-title":"Oral Oncol"},{"key":"2517_CR42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.clon.2010.09.001","volume":"23","author":"X Hou","year":"2011","unstructured":"Hou X, Zhao C, Guo Y, Han F, Lu LX, Wu SX, et al. Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol (R Coll Radiol). 2011;23:128\u201333.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2517_CR43","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ijc.20608","volume":"113","author":"D Chin","year":"2005","unstructured":"Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, et al. Novel markers for poor prognosis in head and neck cancer. Int J Cancer. 2005;113:789\u201397.","journal-title":"Int J Cancer"},{"key":"2517_CR44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1593\/tlo.09109","volume":"2","author":"N Desai","year":"2009","unstructured":"Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2009;2:59\u201364.","journal-title":"Transl Oncol"},{"key":"2517_CR45","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Von Hoff","year":"2011","unstructured":"Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin Oncol. 2011;29:4548\u201354.","journal-title":"J Clin Oncol"},{"key":"2517_CR46","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/JTO.0b013e318217b739","volume":"6","author":"H Shao","year":"2011","unstructured":"Shao H, Tang H, Salavaggione OE, Yu C, Hylander B, Tan W, Repasky E, et al. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer. J Thorac Oncol. 2011;6:998\u20131005.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2517_CR47","first-page":"O-0004","volume":"25","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, Piaza C, Illei P, Brachmann C, Heise C, Pierce D, et al. SPARC analysis in the phase III MPACT trial of nab-paclitaxel (nab-p) plus gemcitabine (gem) vs gem alone for patients with metastatic pancreatic cancer (PC). Ann Oncol. 2014;25(2):O-0004.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2517-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T18:26:35Z","timestamp":1600885595000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2517-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,13]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2517"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2517-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,13]]},"article-number":"464"}}